These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30592762)

  • 1. Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.
    Sampei Z; Haraya K; Tachibana T; Fukuzawa T; Shida-Kawazoe M; Gan SW; Shimizu Y; Ruike Y; Feng S; Kuramochi T; Muraoka M; Kitazawa T; Kawabe Y; Igawa T; Hattori K; Nezu J
    PLoS One; 2018; 13(12):e0209509. PubMed ID: 30592762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.
    Fukuzawa T; Sampei Z; Haraya K; Ruike Y; Shida-Kawazoe M; Shimizu Y; Gan SW; Irie M; Tsuboi Y; Tai H; Sakiyama T; Sakamoto A; Ishii S; Maeda A; Iwayanagi Y; Shibahara N; Shibuya M; Nakamura G; Nambu T; Hayasaka A; Mimoto F; Okura Y; Hori Y; Habu K; Wada M; Miura T; Tachibana T; Honda K; Tsunoda H; Kitazawa T; Kawabe Y; Igawa T; Hattori K; Nezu J
    Sci Rep; 2017 Apr; 7(1):1080. PubMed ID: 28439081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Total Drug Assay for Quantification of Anti-C5 Therapeutic Monoclonal Antibody in the Presence of Abundant Target.
    Watanabe H; Shibuya M; Shibahara N; Ruike Y; Sampei Z; Haraya K; Tachibana T; Wakabayashi T; Sakamoto A; Tsunoda H; Murao N
    AAPS J; 2021 Jan; 23(1):21. PubMed ID: 33415498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action.
    Sheridan D; Yu ZX; Zhang Y; Patel R; Sun F; Lasaro MA; Bouchard K; Andrien B; Marozsan A; Wang Y; Tamburini P
    PLoS One; 2018; 13(4):e0195909. PubMed ID: 29649283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SKY59, A Novel Recycling Antibody for Complement-mediated Diseases.
    Fukuzawa T; Nezu J
    Curr Med Chem; 2020; 27(25):4157-4164. PubMed ID: 31622197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering.
    Hori Y; Ohmine K; Katada H; Noguchi Y; Sato K; Nambu T; Adeline LR; Wan GS; Haraya K; Ozeki K; Nanami M; Tachibana T; Sampei Z; Kuramochi T; Nezu J; Hattori K; Igawa T
    MAbs; 2022; 14(1):2068213. PubMed ID: 35482905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo.
    Igawa T; Maeda A; Haraya K; Tachibana T; Iwayanagi Y; Mimoto F; Higuchi Y; Ishii S; Tamba S; Hironiwa N; Nagano K; Wakabayashi T; Tsunoda H; Hattori K
    PLoS One; 2013; 8(5):e63236. PubMed ID: 23667591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.
    Yuan D; Rode F; Cao Y
    AAPS J; 2018 Mar; 20(3):48. PubMed ID: 29541870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.
    Borrok MJ; Wu Y; Beyaz N; Yu XQ; Oganesyan V; Dall'Acqua WF; Tsui P
    J Biol Chem; 2015 Feb; 290(7):4282-90. PubMed ID: 25538249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.
    Mackness BC; Jaworski JA; Boudanova E; Park A; Valente D; Mauriac C; Pasquier O; Schmidt T; Kabiri M; Kandira A; Radošević K; Qiu H
    MAbs; 2019 Oct; 11(7):1276-1288. PubMed ID: 31216930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K
    Maas BM; Cao Y
    MAbs; 2018; 10(8):1322-1331. PubMed ID: 30130450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models.
    Valente D; Mauriac C; Schmidt T; Focken I; Beninga J; Mackness B; Qiu H; Vicat P; Kandira A; Radošević K; Rao S; Darbyshire J; Kabiri M
    MAbs; 2020; 12(1):1829337. PubMed ID: 33079615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn.
    Yang D; Giragossian C; Castellano S; Lasaro M; Xiao H; Saraf H; Hess Kenny C; Rybina I; Huang ZF; Ahlberg J; Bigwarfe T; Myzithras M; Waltz E; Roberts S; Kroe-Barrett R; Singh S
    MAbs; 2017 Oct; 9(7):1105-1117. PubMed ID: 28786732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.
    Vaccaro C; Zhou J; Ober RJ; Ward ES
    Nat Biotechnol; 2005 Oct; 23(10):1283-8. PubMed ID: 16186811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
    Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
    J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis.
    Zelek WM; Stott M; Walters D; Harris CL; Morgan BP
    Immunology; 2018 Nov; 155(3):396-403. PubMed ID: 29981529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
    Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR
    MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.
    Fung M; Lu M; Fure H; Sun W; Sun C; Shi NY; Dou Y; Su J; Swanson X; Mollnes TE
    Clin Exp Immunol; 2003 Aug; 133(2):160-9. PubMed ID: 12869020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
    Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
    MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.